- Home
- TNGX vs IMTX Comparison
TNGX vs IMTX Comparison
Compare TNGX & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- IMTX
- Stock Information
- Founded
- TNGX 2014
- IMTX N/A
- Country
- TNGX United States
- IMTX Germany
- Employees
- TNGX N/A
- IMTX N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TNGX Health Care
- IMTX Health Care
- Exchange
- TNGX Nasdaq
- IMTX Nasdaq
- Market Cap
- TNGX 723.2M
- IMTX 865.5M
- IPO Year
- TNGX N/A
- IMTX N/A
- Fundamental
- Price
- TNGX $8.76
- IMTX $10.23
- Analyst Decision
- TNGX Strong Buy
- IMTX Strong Buy
- Analyst Count
- TNGX 6
- IMTX 4
- Target Price
- TNGX $10.00
- IMTX $13.67
- AVG Volume (30 Days)
- TNGX 2.1M
- IMTX 1.1M
- Earning Date
- TNGX 11-06-2025
- IMTX 11-17-2025
- Dividend Yield
- TNGX N/A
- IMTX N/A
- EPS Growth
- TNGX N/A
- IMTX N/A
- EPS
- TNGX N/A
- IMTX N/A
- Revenue
- TNGX $24,296,000.00
- IMTX $152,823,253.00
- Revenue This Year
- TNGX $20.42
- IMTX N/A
- Revenue Next Year
- TNGX N/A
- IMTX $13.53
- P/E Ratio
- TNGX N/A
- IMTX N/A
- Revenue Growth
- TNGX N/A
- IMTX 83.61
- 52 Week Low
- TNGX $1.03
- IMTX $3.30
- 52 Week High
- TNGX $9.70
- IMTX $11.25
- Technical
- Relative Strength Index (RSI)
- TNGX 58.17
- IMTX 61.68
- Support Level
- TNGX $8.85
- IMTX $9.72
- Resistance Level
- TNGX $9.31
- IMTX $11.07
- Average True Range (ATR)
- TNGX 0.56
- IMTX 0.69
- MACD
- TNGX 0.08
- IMTX -0.06
- Stochastic Oscillator
- TNGX 67.60
- IMTX 61.65
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.